bepridil has been researched along with Long QT Syndrome in 14 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 9.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| "Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL)." | 9.12 | Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. ( Daida, H; Kawano, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Tokano, T; Yasuda, M, 2006) |
| "Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF)." | 9.12 | Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. ( Fukushima Kusano, K; Hashimoto, T; Hiramatsu, S; Kaseno, K; Miyaji, K; Naito, S; Nakamura, K; Ohe, T; Oshima, S; Tada, H; Tadokoro, K; Taniguchi, K, 2007) |
| "Bepridil has complex pharmacokinetic (PK) properties with large interindividual differences in plasma concentrations." | 6.78 | Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics. ( Hagiwara, N; Hashiguchi, M; Naganuma, M; Shiga, T; Suzuki, A, 2013) |
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 5.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| "Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL)." | 5.12 | Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. ( Daida, H; Kawano, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Tokano, T; Yasuda, M, 2006) |
| "Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF)." | 5.12 | Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. ( Fukushima Kusano, K; Hashimoto, T; Hiramatsu, S; Kaseno, K; Miyaji, K; Naito, S; Nakamura, K; Ohe, T; Oshima, S; Tada, H; Tadokoro, K; Taniguchi, K, 2007) |
| "Bepridil prolongs the QT interval and can induce torsade de pointes." | 4.02 | Relationship between serum bepridil concentration and corrected QT interval. ( Hayakawa, N; Hosomi, K; Kawabata, A; Kusano, K; Matsui, K; Mukai, Y; Nakamura, T; Sakakura, K; Takada, M; Terakawa, N; Wada, K; Yokoyama, S, 2021) |
| "Bepridil has complex pharmacokinetic (PK) properties with large interindividual differences in plasma concentrations." | 2.78 | Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics. ( Hagiwara, N; Hashiguchi, M; Naganuma, M; Shiga, T; Suzuki, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| Matsui, K | 1 |
| Mukai, Y | 1 |
| Sakakura, K | 1 |
| Wada, K | 1 |
| Nakamura, T | 1 |
| Kawabata, A | 1 |
| Terakawa, N | 1 |
| Hayakawa, N | 1 |
| Kusano, K | 1 |
| Hosomi, K | 1 |
| Yokoyama, S | 1 |
| Takada, M | 1 |
| Gravel, AE | 1 |
| Arnold, AA | 1 |
| Dufourc, EJ | 1 |
| Marcotte, I | 1 |
| Shiga, T | 1 |
| Hashiguchi, M | 1 |
| Naganuma, M | 2 |
| Suzuki, A | 1 |
| Hagiwara, N | 1 |
| Sasaoka, S | 1 |
| Matsui, T | 1 |
| Hane, Y | 1 |
| Abe, J | 2 |
| Ueda, N | 1 |
| Motooka, Y | 1 |
| Hatahira, H | 1 |
| Fukuda, A | 1 |
| Hasegawa, S | 1 |
| Kinosada, Y | 1 |
| Nakamura, M | 1 |
| Said, TH | 1 |
| Wilson, LD | 1 |
| Jeyaraj, D | 1 |
| Fossa, AA | 1 |
| Rosenbaum, DS | 1 |
| Kawamura, M | 1 |
| Munetsugu, Y | 1 |
| Tanno, K | 1 |
| Kobayashi, Y | 1 |
| Pareja, K | 1 |
| Chu, E | 1 |
| Dodyk, K | 1 |
| Richter, K | 1 |
| Miller, A | 1 |
| Yoshiga, Y | 1 |
| Shimizu, A | 1 |
| Yamagata, T | 1 |
| Hayano, T | 1 |
| Ueyama, T | 1 |
| Ohmura, M | 1 |
| Itagaki, K | 1 |
| Kimura, M | 1 |
| Matsuzaki, M | 1 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Sawada, Y | 1 |
| Hashimoto, K | 1 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Yasuda, M | 1 |
| Nakazato, Y | 1 |
| Sasaki, A | 1 |
| Kawano, Y | 1 |
| Nakazato, K | 1 |
| Tokano, T | 1 |
| Daida, H | 1 |
| Miyaji, K | 1 |
| Tada, H | 1 |
| Fukushima Kusano, K | 1 |
| Hashimoto, T | 1 |
| Kaseno, K | 1 |
| Hiramatsu, S | 1 |
| Tadokoro, K | 1 |
| Naito, S | 1 |
| Nakamura, K | 1 |
| Oshima, S | 1 |
| Taniguchi, K | 1 |
| Ohe, T | 1 |
| Chouabe, C | 1 |
| Drici, MD | 1 |
| Romey, G | 1 |
| Barhanin, J | 1 |
| Lazdunski, M | 1 |
| Viallon, A | 1 |
| Laporte-Simitsidis, S | 1 |
| Pouzet, V | 1 |
| Venet, C | 1 |
| Tardy, B | 1 |
| Zéni, F | 1 |
| Bertrand, JC | 1 |
5 trials available for bepridil and Long QT Syndrome
| Article | Year |
|---|---|
Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Area Under Curve; Asian People; Atrial Fibrillation; Bepr | 2013 |
Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biphenyl Compounds; Car | 2013 |
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Bisoprolol | 2002 |
Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bepridil; Bradycardi | 2006 |
Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Drug Therapy, Combination; Electrocardi | 2007 |
9 other studies available for bepridil and Long QT Syndrome
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
Relationship between serum bepridil concentration and corrected QT interval.
Topics: Bepridil; Electrocardiography; Humans; Japan; Long QT Syndrome; Retrospective Studies; Torsades de P | 2021 |
An NMR investigation of the structure, function and role of the hERG channel selectivity filter in the long QT syndrome.
Topics: Bepridil; Cetirizine; Dimyristoylphosphatidylcholine; Diphenhydramine; ERG1 Potassium Channel; Ether | 2013 |
Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events.
Topics: Administration, Oral; Aprindine; Bepridil; Databases, Factual; Female; Humans; Long QT Syndrome; Mal | 2016 |
Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Topics: Action Potentials; Animals; Bepridil; Dogs; Dose-Response Relationship, Drug; Electrocardiography; E | 2012 |
Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.
Topics: Bepridil; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Potass | 2013 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers.
Topics: Animals; Benzimidazoles; Bepridil; Calcium Channel Blockers; Cloning, Molecular; COS Cells; Heart; I | 1998 |
[Bepridil: importance of serum level in treatment surveillance].
Topics: Aged; Aged, 80 and over; Bepridil; Dose-Response Relationship, Drug; Drug Monitoring; Electrocardiog | 2000 |